A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
BO45287
Phase 1 other active
Quick answer
A Study to Test How Safe, Effective and How Body’s Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia for Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL) is a Phase 1 program (other) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL)
- Phase
- Phase 1
- Modality
- other
- Status
- active